Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference31 articles.
1. Milestones in the systemic treatment of lung cancer;Pirker;Memo,2017
2. A personalized treatment for lung cancer: molecular pathways, targeted therapie, and genomic characterization;Hensing;Adv. Exp. Med. Biol.,2014
3. Immunotherapy for non-small-cell lung cancer: current status and future obstacles;Cho;Immune Netw.,2017
4. The epidemiology of osteosarcoma;Ottaviani;Cancer Treat. Res.,2009
5. Tumor-immune dynamics regulated in the microenvironment inform the transient nature of immune-induced tumor dormancy;Wilkie;Cancer Res.,2013
Cited by 48 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape;Biomedicine & Pharmacotherapy;2024-02
2. Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer;British Journal of Cancer;2023-12-30
3. Dynamic RBM47 ISGylation confers broad immunoprotection against lung injury and tumorigenesis via TSC22D3 downregulation;Cell Death Discovery;2023-11-30
4. Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer;Discover Oncology;2023-10-19
5. Non-immune cell components in tumor microenvironment influencing lung cancer Immunotherapy;Biomedicine & Pharmacotherapy;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3